Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovetumab in Recurrent Glioblastoma Multiforme
NCT01268566Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jan 2011
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Tovetumab in glioblastoma multiforme (GBM), sponsored by MedImmune. Started Jan 2011; status: completed.
02
Drugs
Tovetumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01268566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01268566.